Chiasm gliomas in pediatric patients. Part 1. Сlinical manifestations

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Chiasm gliomas are very important heterogeneous group of tumors manifesting in the first and second decades of life and is the second leading cause of blindness in children with neurosurgical pathology. It is a benign, slow-growing piloid astrocytoma, accounting for 1–5% of intracranial gliomas in children. The incidence of neurofibromatosis type 1 among patients with chiasm glioma ranges from 7 to 60%. The location of the tumor is determined based on ophthalmological symptoms, neuroimaging data (MRI), and surgical findings. The initial growth of the tumor occurs in the anterior visual pathway structures (optic nerves, chiasm, optic tracts) and leads to ophthalmological symptoms, which are dominant in the clinical manifestations of the disease. Chiasm damage may occur in one or both optic nerves, in one or both optic tracts. Damage to the chiasm manifests as bitemporal heteronymous hemianopsia. Moreover, the spread of the tumor to the optic nerves is accompanied by decreased visual acuity. Damage to the optic tract is manifested by homonymous hemianopia and normal visual acuity. However, isolated damage to the optic tract is uncommon and usually occurs with chiasm and optic nerve lesions; hence, visual disturbances are more complex. Lesions in the optic nerve fibers in the chiasm and optic nerves/tracts lead to primary descending atrophy of the optic nerves. Papilledema with optic nerve atrophy indicates occlusive hydrocephalus. Delayed diagnosis of the disease affects treatment results.

About the authors

Natalya K. Serova

Burdenko National medical research center for Neurosurgery

Author for correspondence.
Email: NSerova@nsi.ru
ORCID iD: 0000-0003-0148-7298
SPIN-code: 5079-8064

MD, Dr. Sci. (Medicine), Рrofessor

Russian Federation, Moscow

Oksana O. Alyaeva

Burdenko National medical research center for Neurosurgery

Email: AlyaevaOO@nsi.ru
ORCID iD: 0009-0007-6157-8382
SPIN-code: 7606-4984

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

References

  1. Yousefi O, Azami P, Sabahi M, et al. Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(19):4781. doi: 10.3390/cancers14194781
  2. Tang Y, Gutmann DH. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects. Cancer Manag Res. 2023;(15):667–681. doi: 10.2147/CMAR.S362678
  3. Serova NK, editor. Clinical neuroophthalmology. Neurosurgical aspects. Tver: Triada; 2011. P. 133–178. (In Russ).
  4. Rosser T, Packer RJ. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol. 2002;17(8):630–637;discussion 646–651. doi: 10.1177/088307380201700815
  5. Korones DN, Padowski J, Factor BA, Constine LS. Do children with optic pathway tumors have an increased frequency of other central nervous system tumors? Neuro Oncol. 2003;5(2):116–120. doi: 10.1093/neuonc/5.2.116
  6. Lourie GL, Osborne DR, Kirks DR. Involvement of posterior visual pathways by optic nerve gliomas. Pediatr Radiol. 1986;16(4):271–274. doi: 10.1007/BF02386860
  7. Shah JR, Patkar DP, Pungavkar SA, Parmer H. Extensive gliomas of visual tract in a patient of neurofibromatosis-I. Indian J Pediatr. 2000;67(12):939–940. doi: 10.1007/BF02723963
  8. Liu GT, Brodsky MC, Phillips PC, et al. Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol. 2004;137(3):407–414. doi: 10.1016/j.ajo.2003.09.055
  9. Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14(6):790–797. doi: 10.1093/neuonc/nos076
  10. Segal L, Darvish-Zargar M, Dilenge ME, et al. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS. 2010;14(2):155–158. doi: 10.1016/j.jaapos.2009.11.020
  11. Prada CE, Hufnagel RB, Hummel TR, et al. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1. J Pediatr. 2015;167(4):851.e1–856.e1. doi: 10.1016/j.jpeds.2015.07.001
  12. Trevisson E, Cassina M, Opocher E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neurooncol. 2017;134(2):279–287. doi: 10.1007/s11060-017-2517-6
  13. Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018;13(1):62. doi: 10.1186/s13023-018-0811-9
  14. Listernick R, Charrow J, Tomita T, Goldman S. Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1. J Neurooncol. 1999;45(2):185–190. doi: 10.1023/a:1006338322266
  15. Grill J, Laithier V, Rodriguez D, et al. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr. 2000;159(9):692–696. doi: 10.1007/s004310000531
  16. Chateil JF, Soussotte C, Pédespan JM, et al. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol. 2001;74(877):24–31. doi: 10.1259/bjr.74.877.740024
  17. Guillamo JS, Créange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126(Pt 1):152–160. doi: 10.1093/brain/awg016
  18. Singhal S, Birch JM, Kerr B, et al. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child. 2002;87(1):65–70. doi: 10.1136/adc.87.1.65
  19. Azizi AA, Walker DA, Liu JF, et al. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2021;23(1):100–111. doi: 10.1093/neuonc/noaa153
  20. Shofty B, Ben Sira L, Constantini S. Neurofibromatosis 1-associated optic pathway gliomas. Childs Nerv Syst. 2020;36(10):2351–2361. doi: 10.1007/s00381-020-04697-1
  21. Gayre GS, Scott IU, Feuer W, et al. Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol. 2001;21(1):1–7. doi: 10.1097/00041327-200103000-00001
  22. Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. 2004;111(3):568–577. doi: 10.1016/j.ophtha.2003.06.008
  23. Wan MJ, Ullrich NJ, Manley PE, et al. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016;129(1):173–178. doi: 10.1007/s11060-016-2163-4
  24. Rassi SZ, Ospina LH, Bochereau A, et al. Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas. Doc Ophthalmol. 2019;139(2):137–149. doi: 10.1007/s10633-019-09703-9
  25. Bowman R, Walters B, Smith V, et al. Visual outcomes and predictors in optic pathway glioma: a single centre study. Eye (Lond). 2023;37(6):1178–1183. doi: 10.1038/s41433-022-02096-1
  26. Kinori M, Armarnik S, Listernick R, et al. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More. Am J Ophthalmol. 2021;(221):91–96. doi: 10.1016/j.ajo.2020.03.053
  27. Jost SC, Ackerman JW, Garbow JR, et al. Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol. 2008;38(12):1293–1299. doi: 10.1007/s00247-008-1003-x
  28. Takenchi H, Kabuto M, Sato K, Kubota T. Chiasmal gliomas with spontaneous regression: proliferation and apoptosis. Childs Nerv Syst. 1997;13(4):229–233. doi: 10.1007/s003810050073
  29. Rubtsova IV, Parsa KF, Hoyt IF. Spontaneous regression of familial optic nerve glioma in a boy with presumed neurofibromatosis type 1 (Recklinghausen disease). The Russian Annals of Ophthalmology. 1998;114(3):48–51. (In Russ).
  30. Valiakhmetova EF, Mazerkina NA, Medvedeva OA, et al. Optic pathway gliomas associated with neurofibromatosis type I in children. Pediatric Hematology/Oncology and Immunopathology. 2019;18(4):29–38. (In Russ). doi: 10.24287/1726-1708-2019-18-4-29-38
  31. Brzowski AE, Bazan C 3rd, Mumma JV, Ryan SG. Spontaneous regression of optic glioma in a patient with neurofibromatosis. Neurology. 1992;42(3 Pt 1):679–681. doi: 10.1212/wnl.42.3.679
  32. Pruzan NL, de Alba Campomanes A, Gorovoy IR, Hoyt C. Spontaneous Regression of a Massive Sporadic Chiasmal Optic Pathway Glioma. J Child Neurol. 2015;30(9):1196–1198. doi: 10.1177/0883073814546686
  33. Ryzhova MV, Galstyan SA, Telysheva EN. Significance of DNA methylation assessment in the morphological diagnosis of brain tumours. Arkhiv Patologii. 2022;84(3):65–75. (In Russ). doi: 10.17116/patol20228403165
  34. Iannaccone A, McCluney RA, Brewer VR, et al. Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol. 2002;105(1):63–81. doi: 10.1023/a:1015719803719
  35. Kelly JP, Leary S, Khanna P, Weiss AH. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology. 2012;119(6):1231–1237. doi: 10.1016/j.ophtha.2011.12.035
  36. Dotto PF, Berezovsky A, Cappellano AM, et al. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1. Doc Ophthalmol. 2018;136(3):177–189. doi: 10.1007/s10633-018-9635-0
  37. Yokoyama S, Takayama K, Sueda M, et al. Optic nerve glioma manifesting as intratumoral hemorrhage in a pregnant woman — case report. Neurol Med Chir (Tokyo). 2003;43(11):559–562. doi: 10.2176/nmc.43.559
  38. Arrese I, Sarabia R, Zamora T. Chiasmal haemorrhage secondary to glioma with unusual MRI appearance. Neurocirugia (Astur). 2014;25(3):136–139. doi: 10.1016/j.neucir.2013.11.001
  39. Walrath JD, Engelbert M, Kazim M. Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. Ophthalmic Plast Reconstr Surg. 2008;24(6):473–475. doi: 10.1097/IOP.0b013e31818beed9

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Field of view. Results of automatic static perimetry (Humphrey C-30): asymmetric chiasmatic syndrome.

Download (191KB)
3. Fig. 2. Field of view. Results of automatic static perimetry (Humphrey C-30): full tractus left-sided homonymous hemianopsia in a patient with right optic tract glioma.

Download (210KB)

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies